Storys zum Thema Krankheit

Folgen
Keine Story zum Thema Krankheit mehr verpassen.
Filtern
  • 01.04.2022 – 09:00

    Chiesi Farmaceutici S.p.A.

    CHIESI GROUP CONTINUES GROWTH

    Parma, Italy (ots/PRNewswire) - - 2021 Turnover €2.42bn - up 8.6% - Internationally China up 22%, US up >10% - Continued focus on innovation: almost 20% of turnover invested in R&D - Chiesi recognised as Top Employer in eight markets and as Top Employer Europe for 10th consecutive year Growth continues at Chiesi, the international research-focussed pharmaceutical group and its 30 global affiliates with turnover at €2.42bn, up 8.6% vs 2020. Gross operating profit (EBITDA) ...

  • 30.03.2022 – 15:00

    Debiopharm International SA

    VIVOSENSE ANNOUNCES CLOSING OF $25M SERIES A FINANCING

    Newport Beach (ots) - Proceeds to accelerate the collection and use of wearable sensor data in clinical trials along with the development of novel digital biomarkers Funding round co-led by the Perceptive Xontogeny Venture (PXV) Fund and Switzerland-based Debiopharm Innovation Fund VivoSense, Inc., (“VivoSense”) an agile end-to-end scientific solutions company developing novel digital endpoints from wearable sensor ...

  • 28.03.2022 – 13:35

    Abcam plc

    Abcam the most awarded company at 2022 industry awards

    Cambridge, England (ots/PRNewswire) - CAMBRIDGE, England, March 25, 2022 Abcam (AIM:ABC); (NASDAQ:ABCM), today announced that it has received six recognitions from CiteAb at their annual industry awards, the highest of any participant evaluated this year. This record number of acknowledgments follows a year of substantial investment for Abcam to enable life sciences researchers from academia and industry to advance ...

  • 25.03.2022 – 14:22

    Abcam

    Abcam the most awarded company at 2022 industry awards

    Cambridge, England (ots/PRNewswire) - CAMBRIDGE, England, March 25, 2022 Abcam (AIM:ABC); (NASDAQ:ABCM), today announced that it has received six recognitions from CiteAb at their annual industry awards, the highest of any participant evaluated this year. This record number of acknowledgments follows a year of substantial investment for Abcam to enable life sciences researchers from academia and industry to advance ...